FDA Approves Binimetinib/Encorafenib for BRAF+ Melanoma

Source: Onclive, June 2018

The FDA has approved the combination of the BRAF inhibitor encorafenib (Braftovi) and the MEK inhibitor binimetinib (Mektovi) for the treatment of patients with BRAF-mutant unresectable or metastatic melanoma, as detected by an FDA-approved test.